Closing

1D

YTD

Market cap

-

52 week high

-

52 week low

-

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

-

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

3

P/E

-

Operating Margin

-

Beta

-

Revenue Growth (Annual)

39.93%

52 week high

-

52 week low

-

Div. Yield

-

EPS Annual Growth

-

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Spectral MD Holdings, Ltd. is a predictive artificial intelligence (AI) company. The Company develops technology using predictive analytics and AI algorithms to help clinicians in making faster treatment decisions in the wound care sector. The Company’s DeepView platform is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. The Company’s DeepView SnapShot wound imaging device is an internally developed multispectral imaging device, which enables the Company to distinguish between damaged and healthy human tissue invisible to the naked eye, providing day one healing assessments for burn wounds and diabetic foot ulcers (DFU). DeepView’s output is engineered to allow the physician to make an informed decision regarding the treatment of the patient’s wound. Its wholly owned subsidiary is Spectral MD UK Ltd.